- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03371836
Use of Clobazam for Epilepsy and Anxiety
February 13, 2021 updated by: Jay Salpekar, M.D., Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
Use of Clobazam in Treating Anxiety Comorbid With Pediatric Epilepsy
This study is an open label, adjunctive, proof of concept, pilot clinical trial.
Pediatric patients with epilepsy and clinically significant anxiety will be recruited and if enrolled will receive active treatment, involving flexible dose titration of clobazam and will be monitored for a period of four months.
The study will be monitored and overseen by the Johns Hopkins Hospital Institutional Review Board.
Study Overview
Study Type
Interventional
Enrollment (Actual)
20
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Maryland
-
Baltimore, Maryland, United States, 21205
- Kennedy Krieger Institute
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
6 years to 17 years (Child)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
Established diagnosis of epilepsy, characterized by focal seizures with suspected or documented localization in the temporal lobe. All participants will have active epilepsy that requires treatment with anticonvulsant medication.
- Although it is not necessary to be seizure free, a seizure baseline period will be established in the 60 days prior to enrollment into the study.
- Current regimen of anticonvulsant drugs must have been stable for 30 days prior to entry into the study.
- No episodes of seizure clusters of status epilepticus within 30 days prior to entry into the study.
- Established symptoms of anxiety with functional impairment.
- A diagnosis of an anxiety disorder based on the administration of the K-SADS Male or female participants equal to or above age 6 and below age 18 at the start of the study. No exclusion will be made on the basis of gender or minority status.
- Male or female participants equal to or above age 6 and below age 18 at the start of the study. No exclusion will be made on the basis of gender or minority status.
- Good general health as determined by medical history and physical examination.
- Ability to swallow pills (participant will receive pill swallowing instruction if necessary). The medicine may be cut into pieces and/or mixed with applesauce.
- If female of childbearing age, a negative urine or serum pregnancy test must be established or assured at baseline. Additionally, the participant must agree to use abstinence or appropriate contraception methods or be otherwise incapable of pregnancy for the duration of the study. Pregnancy test results will be shared with parent or guardian. Pregnancy status (or prevention) and abstinence or contraception methods will be addressed throughout the study for females of childbearing age as well as for post-pubertal males.
- Previous subjects who failed at any point to meet continuation criteria and withdrew early may be considered for re-enrollment by the PI on a case-by-case basis.
- Participant or legal caregiver capable of providing informed consent and fully capable of monitoring the subject's disease process and compliance with treatment.
Exclusion criteria:
- Previous allergic or hypersensitivity reactions to Onfi® or benzodiazepines
- Active substance abuse or dependence within 30 days of enrollment
- DSM-V diagnosis of psychotic illness or imminent risk of harm to self or others.
- Current standing use of benzodiazepines (except as "rescue" medicine)
- Serious or unstable medical or neurologic conditions such as HIV, liver or kidney disease, cancer or diabetes.
- Participation in a previous experimental drug study within 30 days of baseline visit.
- Estimated IQ<70 as indicated by initial clinical assessment (rendering rating scales invalid)
- Insufficient capacity of caregiver or legal guardian to understand and appropriately consent for study procedures
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Clobazam
open label (single treatment arm)
|
Clobazam is used as an adjunct medicine for all participants.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
CGI-I
Time Frame: 14-18 weeks
|
Mean of Clinical Global Impression-Improvement from baseline.
(1-7 point scale; lower score equals a better outcome; 1 is the maximum improvement, 7 is the minimum improvement)
|
14-18 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Jay Salpekar, MD, KKI/JH
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 1, 2017
Primary Completion (Actual)
December 31, 2019
Study Completion (Actual)
December 31, 2019
Study Registration Dates
First Submitted
November 21, 2017
First Submitted That Met QC Criteria
December 12, 2017
First Posted (Actual)
December 13, 2017
Study Record Updates
Last Update Posted (Actual)
March 4, 2021
Last Update Submitted That Met QC Criteria
February 13, 2021
Last Verified
February 1, 2021
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Mental Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Epilepsy
- Anxiety Disorders
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Tranquilizing Agents
- Psychotropic Drugs
- Anti-Anxiety Agents
- GABA Agents
- Anticonvulsants
- GABA-A Receptor Agonists
- GABA Agonists
- Clobazam
Other Study ID Numbers
- onfi90037
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Epilepsy
-
NaviFUS CorporationTaipei Veterans General Hospital, TaiwanCompletedDrug Resistant Epilepsy | Epilepsy, Drug Resistant | Intractable Epilepsy | Refractory Epilepsy | Drug Refractory Epilepsy | Epilepsy, Drug Refractory | Epilepsy, Intractable | Medication Resistant EpilepsyTaiwan
-
Great Ormond Street Hospital for Children NHS Foundation...Active, not recruitingEpilepsies, Partial | Intractable Epilepsy | Focal Epilepsy | Refractory Epilepsy | Epilepsy Intractable | Epilepsy in Children | Epilepsy, FocalUnited Kingdom
-
University of British ColumbiaTerminatedJuvenile Myoclonic Epilepsy | Childhood Absence Epilepsy | Juvenile Absence EpilepsyCanada
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityRecruiting
-
Neuroelectrics CorporationRecruitingEpilepsy | Seizures | Refractory Epilepsy | Epilepsy, Tonic-Clonic | Epilepsy in Children | Seizures, Focal | Focal SeizureSpain, United States, France, Belgium
-
Oslo University HospitalCompletedEpilepsy | Generalized Epilepsy | Focal EpilepsyNorway
-
UCB Pharma SACompletedEpilepsy, Tonic-clonicPoland, Sweden, Hungary, Czechia
-
UCB PharmaCompletedEpilepsy, Tonic-clonic
-
University Hospital, LilleUnknownFocal Epilepsy | Epilepsy IntractableFrance
-
Xuanwu Hospital, BeijingPeking University; Beijing Tiantan Hospital; Qilu Hospital of Shandong University and other collaboratorsNot yet recruitingEpilepsy, Drug ResistantChina
Clinical Trials on Clobazam
-
Lundbeck LLCCompletedEpilepsy | Epilepsy, Generalized | SeizuresUnited States, Belarus, India, Australia, Lithuania
-
Lundbeck LLCCompletedEpilepsy | Epilepsy, Generalized | SeizuresUnited States
-
Boston Children's HospitalLundbeck LLCCompletedElectrical Status Epilepticus in SleepUnited States
-
University Hospital Inselspital, BerneCompleted
-
St. Joseph's Hospital and Medical Center, PhoenixH. Lundbeck A/SUnknownRefractory EpilepsyUnited States
-
University Hospital, GenevaCompleted
-
Lars Kristian MunckPierre and Marie Curie UniversityCompletedBile Acid Malabsorption | Chronic DiarrheaDenmark
-
Instituto de Investigação em ImunologiaButantan InstituteUnknownCancer. | Melanoma. | Ovarian Cancer. | Lung Cancer.Brazil
-
Pavel KleinH. Lundbeck A/SUnknown
-
H. Lundbeck A/STerminatedDravet SyndromeUnited States, Mexico